Posts tagged ‘AUA 2011’
Men in the United States have a 1 in 6 chance of developing prostate cancer in their lifetime. It is, therefore, likely that we all know somebody who has been touched by the disease. To put this data in perspective, approximately 1 in 8 women in the United States will develop breast cancer.
Bone metastases are seen in 90% of men with castration-resistant prostate cancer (CRPC). Patients may experience pain at the site of the metastases, a pain that gradually increases in intensity over time.
Sally Church on Pharma Strategy Blog has written about the experience of her father who died from Prostate Cancer, and the pain he suffered from untreated bone mets.
Source: Presentation by Dr Neil Shore at AUA 2011
In a podcast from AUA 2011 Sally interviewed Dr Neil Shore on Pharma Strategy Blog and asked him why treatment of bone metastases was important, and his views on the risks/benefits associated with denosumab. It is well worth listening to.
Dr Shore will be presenting further data on denosumab and skeletal related events (SREs) at ASCO (Abstract #4533)
The 2011 annual meeting of the American Urological Association (AUA) ended in Washington DC today.
Some of the highlights of the meeting were written about on Pharma Strategy Blog and Biotech Strategy Blog, these include:
PIVOT (Prostate Cancer Intervention versus Observation Study)
The data from this study was presented in Tuesday’s plenary session by Dr Tim Wilt, a Professor at the University of Minnesota, and was to many attendees, the highlight of the meeting.
The trial results showed for the first time that radical prostatectomy (RP) is no better than watchful waiting in men with early stage prostate cancer using evidence based medicine.
This groundbreaking research is likely to have a major impact on urology practice in the United States.
Pieter Droppert wrote about the PIVOT results on Biotech Strategy Blog. Scott Hensley on NPR’s Health Blog, “Shots” references Pieter’s post, and has an interview with Dr Wilt that is also well worth reading.
Also presented at AUA in Tuesday’s plenary session were the results from:
Denosumab (Xgeva®) 147 phase III trial
This study looked at castrate resistant prostate cancer patients at high risk of development of bone metastasis.
Sally Church on Pharma Strategy Blog discusses the results presented by Dr Matthew Smith at AUA. Denosumab was shown to increase bone metastasis-free survival and delayed time to first bone metastasis, but did not increase overall survival (OS).
Both Sally Church and Pieter Droppert also wrote additional blog posts from the meeting. On Biotech Strategy Blog, Pieter wrote about data that showed:
He also wrote about:
New Prostate Cancer products in development beyond the androgen axis
Some of the new products mentioned in Pieter’s post include alpharadin, XL-184 (cabozantinib), Prostvac-VF, BPX-101 and ipilimumab. You can read more on Biotech Strategy Blog.
Meanwhile on Pharma Strategy Blog, Sally Church continued one of her themes of how social media is impacting medical conferences by reviewing:
How AUA have embraced Social Media in 2011
Sally also recorded a video blog post (vlog) from AUA that highlighted some of the exciting developments in basic biology and how this may lead to new Prostate Cancer treatments in the future. Click here to watch this.
If you were unable to attend the meeting, Sally aggregated the #AUA2011 tweets.
Selecting what to write about on a blog is subjective, so the above posts are not intended to provide comprehensive meeting or conference coverage, only a few highlights of what was presented at the highly informative and educational AUA annual meeting.
If you are interested in a more comprehensive report on the Prostate Cancer Market and the emerging new products in development, please do not hesitate to contact us.
Sally Church on Pharma Strategy Blog has published a video blog (vlog) post on what’s hot in Prostate Cancer at the 2011 AUA (American Urological Association) annual meeting in Washington DC.
In her post, Sally reviews presentations by Charles Sawyers and Oliver Sartor. She discusses new prostate cancer products in development such as MDV3100 and custirsen (OGX-011), and how our understanding of basic biology may lead to new combinations in the future.
If you missed Sally’s video blog post, then you can watch it on Vimeo below. As Sally would say, “check it out!”
Sally Church on Pharma Stratagy Blog is aggregating the tweets from the 2011 Annual Meeting of the American Urological Association (AUA). Twitter hashtag #AUA2011.
If you are unable to attend the meeting, you can follow what’s happening on Pharma Strategy Blog.
Icarus Consultants will be attending the annual meeting of the American Urological Association (AUA) that starts in Washington DC this weekend.
On Biotech Strategy Blog, Pieter Droppert has written about the independent satellite symposia he will be attending. These are not officially part of the AUA meeting, but associated with it.
One of the symposia is on managing skeletal-related events in patients with prostate cancer. In his blog post, Pieter discusses some of the unanswered questions around this topic such as the impact on Quality of Life (QoL) in patients with bone-metastatic castrate resistant prostate cancer (CRPC).
You can read more about which AUA satellite symposia Pieter will be attending and what information and insight he hopes to obtain from them on Biotech Strategy Blog.